Biotech Firms Deploy AI Across Drug Discovery, Health Testing, Therapy

Artificial intelligence is increasingly transforming the biopharma and biomedical research sectors, offering breakthroughs in drug discovery, disease detection, and personalized therapies. Experts emphasize AI's long-term potential in decoding biology and designing genetic medicines, with startups like Viome using AI-driven analyses of microbiomes and RNA to personalize health recommendations and detect early disease signs. Cell and gene therapies, bolstered by AI in target identification and development, are expanding beyond oncology into autoimmune, neurological, and cardiovascular diseases, with the market projected to grow rapidly. New open-source tools like BioChatter facilitate integrating conversational AI with biomedical knowledge graphs, enhancing research workflows and reproducibility in biomedical natural language processing. Additionally, generative AI is addressing operational challenges in biopharma manufacturing by aggregating and analyzing siloed data to improve yield and product quality, marking a shift toward smarter, more predictive biopharma operations. Collectively, these advances illustrate AI's critical role in revolutionizing healthcare and biopharma industries through improved precision, efficiency, and innovation.